86. 肺動脈性肺高血圧症 Pulmonary arterial hypertension Clinical trials / Disease details
臨床試験数 : 1,205 / 薬物数 : 684 - (DrugBank : 124) / 標的遺伝子数 : 100 - 標的パスウェイ数 : 193
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03344159 (ClinicalTrials.gov) | April 1, 2018 | 28/9/2017 | Spironolactone Therapy in Chronic Stable Right HF Trial | Spironolactone Therapy in Chronic Stable Right HF Trial | Chronic Right-Sided Heart Failure;Pulmonary Arterial Hypertension;Pulmonary Hypertension, Primary, 2;Pulmonary Hypertension, Primary, 3;Pulmonary Hypertension, Primary, 4;Cardiomyopathy Right Ventricular | Drug: Spironolactone;Drug: Placebo;Radiation: PET/CT Scan: Two PET scans using 1. C-11 HED and 2. N-13 Ammonia or rubidium-82;Diagnostic Test: Cardiac MRI (Gadolinium enhanced) | Ottawa Heart Institute Research Corporation | NULL | Completed | 18 Years | N/A | All | 15 | Phase 4 | Canada |
2 | NCT02253394 (ClinicalTrials.gov) | September 2015 | 17/9/2014 | The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study | The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study (The CAPS-PAH Study) | Pulmonary Arterial Hypertension | Drug: Ambrisentan plus Spironolactone;Drug: Ambrisentan plus Placebo | Brigham and Women's Hospital | Gilead Sciences | Terminated | 18 Years | N/A | All | 2 | Phase 4 | United States |
3 | NCT01712620 (ClinicalTrials.gov) | January 10, 2014 | 20/10/2012 | Spironolactone for Pulmonary Arterial Hypertension | A Pilot Study of the Effect of Spironolactone Therapy on Exercise Capacity and Endothelial Dysfunction in Pulmonary Arterial Hypertension | Pulmonary Arterial Hypertension | Drug: Spironolactone;Drug: Placebo | National Institutes of Health Clinical Center (CC) | National Heart, Lung, and Blood Institute (NHLBI);National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);University of Pennsylvania;University of Maryland Medical Center;Medstar Health Research Institute;New England Medical Center, Tufts University School of Medicine | Recruiting | 18 Years | N/A | All | 70 | Phase 2 | United States |
4 | NCT01468571 (ClinicalTrials.gov) | July 2011 | 3/11/2011 | Effects of Spironolactone on Collagen Metabolism in Patients With Pulmonary Arterial Hypertension | Effects of Spironolactone on Collagen Metabolism in Pulmonary Arterial Hypertension | Pulmonary Hypertension | Drug: Spironolactone;Drug: Placebo | Baylor College of Medicine | National Heart, Lung, and Blood Institute (NHLBI) | Recruiting | 18 Years | N/A | Both | 50 | Phase 4 | United States |
5 | NCT00811486 (ClinicalTrials.gov) | January 2009 | 18/12/2008 | Body Volume Regulation in Pulmonary Arterial Hypertension With Right Ventricular Failure | Body Volume Regulation in Pulmonary Arterial Hypertension With Right Ventricular Failure | Right Heart Failure;Pulmonary Hypertension | Drug: Spironolactone and conivaptan | University of Colorado, Denver | NULL | Withdrawn | 18 Years | 75 Years | Both | 0 | N/A | United States |
6 | NCT00240656 (ClinicalTrials.gov) | October 2005 | 17/10/2005 | Spironolactone Combined With Captopril and Carvedilol for the Treatment of Pulmonary Arterial Hypertension | Official Title: Spironolactone Combined With Captopril and Carvedilol for the Treatment of Patients With Pulmonary Arterial Hypertension Associated With Congenital Heart Disease—Focus on Pulmonary Artery Remodeling | Hypertension, Pulmonary | Drug: spironolactone captopril carvedilol | Hebei Medical University | NULL | Completed | N/A | 80 Years | Both | Phase 1 | China |